{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:08:11Z","timestamp":1785413291986,"version":"3.56.0"},"reference-count":36,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Roche Diagnostics GmbH","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating tumor antigens (ctA; tumor markers) are blood-based proteins that can offer prognostic value in non-small cell lung cancer (NSCLC) and may serve as potential early surrogates for survival. Given the significantly reduced testing time and cost of ctA compared with circulating tumor DNA (ctDNA), we further explored the utility of ctA using samples collected from over 2,300 patients participating in five clinical trials (IMpower130, 131, 132, 150, and 110).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed a panel of six ctA (CA125 (cancer antigen 125), CEA (carcinoembryonic antigen), Cyfra21-1 (cytokeratin 19 fragment 21-1; CYFRA), NSE (neuron-specific enolase), SCC (squamous cell carcinoma antigen), and ProGRP (progastrin-releasing peptide)) and CRP (C-reactive protein) from the serum of patients with metastatic NSCLC in these trials, which investigated combinations of atezolizumab (anti-programmed death-ligand 1)\u00b1bevacizumab\u00b1chemotherapy. Previous work showed that an optimized cut-off using two ctA or a machine learning (ML) model of ctDNA features, both taken at 6 weeks, can stratify patients with stable disease (SD) for survival risk in IMpower150. Building on this approach, we applied an ML model combining ctA features at baseline and at 6\u2009weeks, trained across a much larger aggregate dataset from multiple clinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Previous findings from ctA analysis of IMpower150 were confirmed and found to be applicable to several other trials analyzed in this study. We found that ML model predictions provided similar prognostic performance (c-index of 0.73 and 0.71 in squamous and non-squamous test datasets, respectively), with CYFRA being the top feature for both histologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While ctA demonstrated limited potential in differentiating treatment effects to inform early drug development, deriving an optimal prediction cut-off for 1-year overall survival (OS) showed that ctA model predictions could effectively stratify patients by radiographic response with 61% sensitivity and 78% specificity, adding significant prognostic value to radiographic imaging. Patients with partial response (PR), progressive disease (PD), or stable disease (SD) at either 6 weeks of treatment or best confirmed overall response could be separated into low-risk or high-risk groups for OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014710","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:40:19Z","timestamp":1785411619000},"page":"e014710","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-818X","authenticated-orcid":false,"given":"Charles W","family":"Tran","sequence":"first","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zou","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe J","family":"Assaf","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Mang","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH Penzberg, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8370-1403","authenticated-orcid":false,"given":"Francesco","family":"Ranucci","sequence":"additional","affiliation":[{"name":"Roche Diagnostics SL, Sant Cugat del Vall\u00e8s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H","family":"Cheng","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Estay","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vy","family":"Ma","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minu K","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Shames","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Holdenrieder","sequence":"additional","affiliation":[{"name":"German Heart Centre Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-4462","authenticated-orcid":false,"given":"Martin","family":"Reck","sequence":"additional","affiliation":[{"name":"Thoracic Oncology, LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzent","family":"Rolny","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH Penzberg, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Schulze","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Wehnl","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH Penzberg, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-684X","authenticated-orcid":false,"given":"Namrata S","family":"Patil","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2026073004401288000_14.7.e014710.1","unstructured":"Society, A.C . Cancer facts & figures, 1930. 2025. Available: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf"},{"key":"2026073004401288000_14.7.e014710.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01029-8"},{"key":"2026073004401288000_14.7.e014710.3","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026073004401288000_14.7.e014710.4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026073004401288000_14.7.e014710.5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041284","article-title":"The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer","volume":"15","author":"de Abreu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026073004401288000_14.7.e014710.6","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J Clin Invest"},{"key":"2026073004401288000_14.7.e014710.7","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1158\/1538-7445.AM2022-5916","article-title":"Abstract 5916: Tumor-informed patient-specific panel outperforms tumor-na\u00efve and tumor-informed fixed panel for circulating tumor DNA (ctDNA)-based postoperative monitoring of non-small cell lung cancer (NSCLC)","volume":"82","author":"Chen","year":"2022","journal-title":"Cancer Res"},{"key":"2026073004401288000_14.7.e014710.8","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216505","article-title":"Comparison of tumor-informed and tumor-na\u00efve sequencing assays for ctDNA detection in breast cancer","volume":"15","author":"Santonja","year":"2023","journal-title":"EMBO Mol Med"},{"key":"2026073004401288000_14.7.e014710.9","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.95"},{"key":"2026073004401288000_14.7.e014710.10","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.21037\/jtd.2016.08.72","article-title":"Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer","volume":"8","author":"Oh","year":"2016","journal-title":"J Thorac Dis"},{"key":"2026073004401288000_14.7.e014710.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101039","article-title":"Neuron specific enolase promotes tumor metastasis by activating the Wnt\/\u03b2-catenin pathway in small cell lung cancer","volume":"14","author":"Zha","year":"2021","journal-title":"Transl Oncol"},{"key":"2026073004401288000_14.7.e014710.12","first-page":"61","article-title":"Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer","volume":"53","author":"Pujol","year":"1993","journal-title":"Cancer Res"},{"key":"2026073004401288000_14.7.e014710.13","doi-asserted-by":"publisher","DOI":"10.1038\/srep09444"},{"key":"2026073004401288000_14.7.e014710.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246486","article-title":"C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients","volume":"16","author":"Patil","year":"2021","journal-title":"PLoS One"},{"key":"2026073004401288000_14.7.e014710.15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023"},{"key":"2026073004401288000_14.7.e014710.16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"2026073004401288000_14.7.e014710.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"2026073004401288000_14.7.e014710.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"2026073004401288000_14.7.e014710.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028"},{"key":"2026073004401288000_14.7.e014710.20","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTHO.2020.11.025"},{"key":"2026073004401288000_14.7.e014710.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"2026073004401288000_14.7.e014710.22","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.3233\/TUB-230001","article-title":"Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150","volume":"46","author":"Mang","year":"2024","journal-title":"Tumour Biol"},{"key":"2026073004401288000_14.7.e014710.23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"key":"2026073004401288000_14.7.e014710.24","doi-asserted-by":"crossref","unstructured":"Chen T , Guestrin C . XGBoost: a scalable tree boosting system. Proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining, New York, NY, USA: Association for Computing Machinery, (KDD \u201916); 2016:785\u201394. Available: https:\/\/dl.acm.org\/doi\/10.1145\/2939672.2939785","DOI":"10.1145\/2939672.2939785"},{"key":"2026073004401288000_14.7.e014710.25","unstructured":"Lundberg SM , Lee SI . A unified approach to interpreting model predictions. Proceedings of the 31st international conference on neural information processing systems, Red Hook, NY, USA: Curran Associates Inc, (NIPS\u201917); 2017:4768\u201377."},{"key":"2026073004401288000_14.7.e014710.26","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.3233\/TUB-230021","article-title":"Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations","volume":"46","author":"Trulson","year":"2024","journal-title":"Tumour Biol"},{"key":"2026073004401288000_14.7.e014710.27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604157"},{"key":"2026073004401288000_14.7.e014710.28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601851"},{"key":"2026073004401288000_14.7.e014710.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-11312-4","article-title":"Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"2026073004401288000_14.7.e014710.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"2026073004401288000_14.7.e014710.31","doi-asserted-by":"crossref","first-page":"101381","DOI":"10.1016\/j.eclinm.2022.101381","article-title":"Elevated tumor markers for monitoring tumor response to immunotherapy","volume":"46","author":"Yang","year":"2022","journal-title":"eClinicalMedicine"},{"key":"2026073004401288000_14.7.e014710.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2011.01.010"},{"key":"2026073004401288000_14.7.e014710.33","doi-asserted-by":"crossref","unstructured":"Xu Y , Xu L , Qiu M , et al . Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer. Sci Rep 2015;5. doi:10.1038\/srep09444","DOI":"10.1038\/srep09444"},{"key":"2026073004401288000_14.7.e014710.34","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/cam4.493","article-title":"Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer","volume":"4","author":"Zhang","year":"2015","journal-title":"Cancer Med"},{"key":"2026073004401288000_14.7.e014710.35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14022"},{"key":"2026073004401288000_14.7.e014710.36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/jca.78574","article-title":"Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC","volume":"14","author":"Buresova","year":"2023","journal-title":"J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:40:24Z","timestamp":1785411624000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2025-014710"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014710","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}